Chronic Disease Trends Will Ignite Subcutaneous Drug Delivery
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
18 May 25
Updated
15 Aug 25
AnalystHighTarget's Fair Value
US$91.00
23.1% undervalued intrinsic discount15 Aug
US$69.98
1Y
14.9%7D
9.3%